Sino Medical Sciences Technology Inc. (SINOMED) announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). Once completed, the company plans to submit the data to the U.S. Food and Drug Administration and Japanese Pharmaceuticals and Medical Devices Agency for the device approval. The PIONEER III trial completed follow-up of 1,631 patients at 74 sites in North America, Europe and Japan. Patients presenting with symptomatic heart disease were randomized 2:1 to receive the BuMA Supreme DES or any commercially available durable polymer everolimus-eluting stent. The clinical trial's endpoint is target lesion failure (TLF) at twelve months and patients will be followed-up for five years post study enrollment. Additionally, the trial is powered for a long-term landmark analysis of TLF between one and five years; looking for superiority of the BuMA Supreme over the control arm. The BuMA Supreme is a new evolution of DES, developed to maximize functional healing of the blood vessels after a stent implantation. Its innovative design utilizes a combination of a novel drug release kinetic and proprietary coating technology to allow for a quicker return of natural cellular functionality, in comparison to other commercially available DES. This healthy restoration is believed to contribute to better long-term clinical outcomes. The BuMA Supreme with a new cobalt chromium platform and delivery system is CE approved and available for distribution in select regions. BuMA Supreme is an investigational device in the United States and Japan.